Julian Symons
Technik-/Wissenschafts-/F&E-Leiter bei ALIGOS THERAPEUTICS, INC.
Vermögen: 322 344 $ am 30.04.2024
Aktive Positionen von Julian Symons
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2018 | - |
Karriereverlauf von Julian Symons
Ehemalige bekannte Positionen von Julian Symons
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01.01.2013 | 01.04.2018 |
Ausbildung von Julian Symons
| University of Central Lancashire | Undergraduate Degree |
| York University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| Vereinigtes Königreich | 2 |
| Kanada | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Julian Symons
- Erfahrung
